Amgen and Cytokinetics claim heart drug success, but results widely disappoint

A closely watched study of an experimental heart drug being developed by Amgen, biotech Cytokinetics and France's Servier succeeded on its main goal, the companies said Thursday, but a weaker-than-expected result appeared to raise doubts about the medicine's potential.